Bank of Hawai‘i Corporation Third Quarter 2026 Financial Results

Impact · against what's priced in

Bank of Hawai‘i's Q3 results show a plateau in profitability, with net income growth of only 0.7% and a slight dip in ROE to 15.38%. This marginal sequential performance suggests limited organic expansion, tempering any bullish expectations for significant near-term growth.

BOH+0.10: No priced-in read yet
In context: The company reported a modest sequential increase in EPS to $1.49 and net income to $64.3 million, though the 9bps drop in ROE suggests profitability is flattening.
Read from the article alone

Bank of Hawai‘i Corporation Third Quarter 2026 Financial Results

earnings▲25%
banking
BOH
equity returns
net income

Top 1 mover · tap to explore

Bank of Hawai‘i Corporation Third Quarter 2026 Financial Results

What matters in this story

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

Bank of Hawai‘i Corporation Third Quarter 2026 Financial Results

What matters in this story

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

How each ticker is affected

Track these names every morning.

Chevron Eyes 150% EPS Jump on Oct. 30 — But Are the Risks Already Priced In?

Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?

As BP Flags Up to $4.5B in Write-Downs, Can a Production Surge Save the Day on Oct. 30?

Eni: 3 Key Takeaways for Long-Term Investors

Bank of Hawai‘i Corporation Third Quarter 2026 Financial Results

What matters in this story

Next reads from the same story arc

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

Bank of Hawai‘i Corporation Third Quarter 2026 Financial Results

What matters in this story

Next reads from the same story arc

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

How each ticker is affected

Track these names every morning.

Chevron Eyes 150% EPS Jump on Oct. 30 — But Are the Risks Already Priced In?

Is AstraZeneca's Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?

As BP Flags Up to $4.5B in Write-Downs, Can a Production Surge Save the Day on Oct. 30?

Eni: 3 Key Takeaways for Long-Term Investors